English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Basic science has always been the engine behind the technological evolution of the cardiovascular field. In the late 90s and early 2000s, cardiovascular research reached the peak of its productivity, with rapid translation of novel ideas from the bench to clinical practice, leading to an impressive enhancement in the quality of life and life expectancy of patients with cardiovascular diseases. Although large pharmaceutical companies have tended to close their RandD departments, there has been a large influx of public investment for cardiovascular basic research in the last years. As reported by the ESC in Cardioscape, at least 876 million euros were awarded for cardiovascular disease  research project grants under competitive open funding schemes in the EU over the 2010 – 2012 period

cardiovascular research

Scientists of Tomorrow at the Frontiers of Cardiovascular Biology 2016 in Florence: translating basic science into clinical practice is the next frontier